Tag: Vasculitis

The incidence of hydralazine-induced ANCA vasculitis is dose-dependent, rising from 5.4% in patients taking 100 mg/day to 10.4% for those on 200 mg/day for over three years [1.7.2]. So, what are the symptoms of hydralazine induced vasculitis to watch for?

Affecting millions over the age of 50, giant cell arteritis (GCA) is a systemic vasculitis that can lead to severe complications, including permanent vision loss if not treated promptly. A key component of modern therapy for this condition is the **injection for giant cell arteritis**, primarily the biologic medication tocilizumab (Actemra), which targets the inflammatory pathways involved in the disease.

Doxycycline is one of the most commonly prescribed antibiotics in the US, with over 5 million prescriptions annually, yet cases suggesting a link to vasculitis are exceedingly rare. Though vasculitis can be triggered by medications, the connection between **doxycycline and vasculitis** is not well-established and primarily documented through isolated case reports, not large-scale studies.

As a cornerstone in the treatment of many autoimmune conditions, methotrexate (MTX) is frequently prescribed for vasculitis, leveraging its potent immunomodulatory effects to reduce inflammation. This article explores **how does methotrexate work for vasculitis**, detailing its complex mechanisms that help control disease activity and induce remission.

In clinical trials for non-Hodgkin's lymphoma, the median time to response was approximately 50 days (about 7 weeks) following a Rituxan infusion. However, the answer to how long does it take for a Rituxan infusion to work varies significantly depending on the treated condition, with some patients noticing improvement much later.

Approximately 85% of generalized myasthenia gravis cases are driven by an immune system attack, highlighting the role of complement inhibitors like Eculizumab and avacopan. What is the difference between Eculizumab and avacopan, and how do their targeted actions impact treatment for various autoimmune conditions?

Originally developed in the 1960s as a treatment for parasitic infections, levamisole was withdrawn from human markets in many countries due to dangerous side effects. Today, the question of **what kind of drug is levamisole** is complicated by its widespread, and often unrecognized, use as a toxic adulterant in illicit street drugs, with some reports finding it in over 80% of seized cocaine.

According to the Drug Enforcement Administration (DEA), at times, up to 82% of cocaine seized in the United States has been found to be adulterated with levamisole [1.9.2]. The answer to **Is levamisole toxic to humans?** is a definitive yes, with risks ranging from autoimmune disorders to death.

Behçet's disease, a rare inflammatory disorder, has a global prevalence estimated at 10.3 per 100,000 people [1.7.6]. Answering 'What is the drug of choice for Behçet's disease?' is complex, as no single medication is universally effective; treatment is tailored to the specific organ systems involved and symptom severity [1.3.3].

According to the Phase 3 ADVOCATE trial, approximately 10% of patients taking avacopan reported fatigue as an adverse event. This means that while some individuals may experience increased tiredness while on the medication, it is not an issue for everyone. It's important for patients to consider that their underlying condition, ANCA-associated vasculitis, is a known cause of debilitating fatigue, which complicates identifying the specific source of tiredness.